Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Status:
RECRUITING
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded, randomized placebo-controlled clinical trial.
Phase:
PHASE2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China First Affiliated Hospital of Harbin Medical University First Affiliated Hospital of Xinjiang Medical University Shanxi Bethune Hospital Sichuan Provincial People's Hospital Tang-Du Hospital The First Affiliated Hospital of Nanchang University The First Affiliated Hospital of Zhengzhou University Xiangya Hospital of Central South University